Skip to main content

Table 3 Statistically significant correlations between the 8 monocyte surface antigens under study, for the particular subgroups

From: Surface antigen expression on peripheral blood monocytes in women with gynecologic malignancies

Endometrial Cancer (N = 42) Cervical Cancer (N = 13) Ovarian Cancer (N = 14) Group I (N = 20) Group II (N = 23)
CD11a vs. CD54 (r = 0.444920; p = 0.0032) (−) CD11a vs. CD54 (r = 0.606311; p = 0.0216) (−) (−)
CD11b vs. CD64 (r = 0.390416; p = 0.0106) CD11b vs. CD64 (r = 0.556329; p = 0.0484) (−) (−) CD11b vs. CD64 (r = 0.534304; p = 0.0087)
(−) CD11b vs. CD62 L (r = 0.789189; p = 0.0014) (−) (−) (−)
(−) CD11c vs. CD64 (r = − 0.645134; p = 0.0173) (−) (−) (−)
(−) CD11c vs. HLA-DR (r = 0.672398; p = 0.0119) (−) CD11c vs. HLA-DR (r = 0.445866; p = 0.0488) (−)
(−) (−) CD16 vs. CD62 L (r = 0.554456; p = 0.0397) (−) (−)
(−) (−) (−) (−) CD16 vs. HLA-DR (r = − 0.506677; p = 0.0137)
CD54 vs. CD62 L (r = 0.518139; p = 0.0005) CD54 vs. CD62 L (r = 0.570250; p = 0.0419) CD54 vs. CD62 L (r = 0.550661; p = 0.0413) (−) CD54 vs. CD62 L (r = 0.426489; p = 0.0425)
(−) (−) (−) CD54 vs. HLA-DR (r = −0.476692; p = 0.0336) (−)
  1. Group I - women operated but had no malignancy in postoperative histopathologic examination, Group II - healthy women. r - Spearman correlation coefficient.